Results 51 to 60 of about 931,361 (287)

Clinical Characteristics and Prognostic Risk Factors for Pediatric B‐Cell Lymphoblastic Lymphoma: A Multicenter Retrospective Cohort Study for China Net Childhood Lymphoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background B‐cell lymphoblastic lymphoma (B‐LBL) represents a rare variety of non‐Hodgkin lymphoma, with limited research on its biology, progression, and management. Methods A retrospective analysis was performed on the clinical characteristics of 256 patients aged ≤18 years who received treatment under the China Net Childhood Lymphoma (CNCL)‐
Zhijuan Liu, Jian Wang, Ling Jin, Yanlong Duan, Fu Li, Yueping Jia, Leping Zhang, Xiaojun Yuan, Wei Liu, Ying Liu, Ansheng Liu, Mincui Zheng, Yunpeng Dai, Lian Jiang, Lirong Sun, Xiaowen Zhai, Rong Liu, Chunju Zhou, Zifen Gao, Yonghong Zhang, Xiaomei Yang   +20 more
wiley   +1 more source

libtissue - implementing innate immunity [PDF]

, 2006
In a previous paper the authors argued the case for incorporating ideas from innate immunity into articficial immune systems (AISs) and presented an outline for a conceptual framework for such systems.
Aickelin, Uwe, Twycross, Jamie
core   +3 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Antibody-gamma/delta T cell receptors targeting GPC2 regress neuroblastoma with low antigen density

Cell Reports Medicine
Summary: Chimeric antigen receptor (CAR) T cells have shown promise in hematological cancers but face challenges in solid tumors, partly due to heterogeneous antigen density. Glypican-2 (GPC2) is an oncofetal antigen highly expressed in neuroblastoma and
Alex Quan, Mingyu Huo, Dan Li, Laura E. Hutchins, Constanza Rodriguez, Jangsuk Oh, Hsi-En Tsao, Madeline Spetz, Elijah Edmondson, Dana Ashworth, Rui Zheng, Jing Zhou, Jinyun Chen, Jingbao Liu, Guangyan Xiong, Hongbing Zhang, Cheng Liu, Rosa Nguyen, Nan Li, Mitchell Ho   +19 more
doaj   +1 more source

Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors. [PDF]

, 2019
In 2017, the US Food and Drug Administration approved the first two novel cellular immunotherapies using synthetic, engineered receptors known as chimeric antigen receptors (CARs), tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta ...
Baybutt, Trevor R., Caparosa, Ellen M., Flickinger, John C., Snook, Adam E.   +3 more
core   +1 more source

Genomic donor cassette sharing during VLRA and VLRC assembly in jawless vertebrates

, 2014
Lampreys possess two T-like lymphocyte lineages that express either variable lymphocyte receptor (VLR) A or VLRC antigen receptors. VLRA+ and VLRC+ lymphocytes share many similarities with the two principal T-cell lineages of jawed vertebrates expressing
Aravind, L., Boehm, T., Cooper, M., Das, S., Hirano, M., Holland, S., Iyer, L., Li, J., Schorrp, M.   +8 more
core   +1 more source

Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. [PDF]

, 2015
Cytotoxic T cells recognize, via their T cell receptors (TCRs), small antigenic peptides presented by the major histocompatibility complex (pMHC) on the surface of professional antigen-presenting cells and infected or malignant cells. The efficiency of T
Alam, Aleksic, Aleksic, Alexander-Miller, Angelov, Artyomov, Atkins, Au-Yeung, Bachmann, Besser, Besser, Black, Boon, Borbulevych, Bos, Boulter, Brahmer, Brentville, Bridgeman, Bullock, Busch, Cameron, Campoli, Carreno, Carreno, Casas, Cebecauer, Chen, Chen, Chervin, Chlewicki, Cole, Corr, Corse, Corse, Coulie, Couzin-Frankel, Cukalac, Davis, Derby, Dolton, Dudley, Dudley, Dunn, Dushek, Dutoit, Dutoit, Dvorak, Dzutsev, Edwards, Engels, Engels, Faroudi, Fivash, Foley, Fonteneau, Fridman, Gallimore, Gannon, Garon, Gill, Gonzalez, Govern, Guillaume, Guy, Haidar, Hebeisen, Hebeisen, Hebeisen, Hodi, Holler, Holler, Holler, Hombrink, Hong, Huang, Huppa, Irving, Janicki, Jiang, Johnson, June, Kalergis, Keane, Kedl, Kersh, Klebanoff, Klein, Knabel, Krogsgaard, Kronig, Kunert, Kurts, Kyewski, La Gruta, Laugel, Li, Linette, Liu, Liu, Lovgren, Malecek, Malherbe, Matsui, McKeithan, McMahan, McMahan, Mellman, Morgan, Morgan, Nauerth, Nauerth, Neudorfer, Overwijk, Pages, Palmer, Palmer, Postow, Price, Pryshchep, Radvanyi, Restifo, Riquelme, Robbins, Robbins, Robbins, Robert, Robert, Romero, Rosenberg, Rosenberg, Rosenberg, Rosette, Salter, Savage, Schmid, Schmidt, Schmidt, Schmitt, Schumacher, Schwartzentruber, Slansky, Speiser, Speiser, Stone, Stone, Sykulev, Tan, Thomas, Tian, Topalian, Trautmann, Turner, Turula, Valitutti, Valitutti, Verdeil, Vigano, Vigano, Wang, Weiss, Wiedemann, Wilde, Wooldridge, Yee, Yee, Yeh, Zeh, Zehn, Zehn, Zehn, Zhao, Zhong, Zhu, Zhu, Zoete, Zoete   +176 more
core   +1 more source

Next-Generation Chimeric Antigen Receptor T-cells

Hematology/Oncology and Stem Cell Therapy, 2022
The U.S. Food and Drug Administration (FDA) approved 6 CAR T cell (CAR-T) products, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel) in the last 5 ...
Dongni, Yi, Mia, Gergis, Jingmei, Hsu, Yang, Yang, Xia, Bi, Mahmoud, Aljurf, Usama, Gergis   +6 more
openaire   +2 more sources

Spatiotemporal and quantitative analyses of phosphoinositides – fluorescent probe—and mass spectrometry‐based approaches

FEBS Letters, EarlyView.
Fluorescent probes allow dynamic visualization of phosphoinositides in living cells (left), whereas mass spectrometry provides high‐sensitivity, isomer‐resolved quantitation (right). Their synergistic use captures complementary aspects of lipid signaling. This review illustrates how these approaches reveal the spatiotemporal regulation and quantitative
Hiroaki Kajiho, Shin Morioka, Junko Sasaki, Takehiko Sasaki   +3 more
wiley   +1 more source

T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road

Cells, 2020
T-cells have a natural ability to fight cancer cells in the tumour microenvironment. Due to thymic selection and tissue-driven immunomodulation, these cancer-fighting T-cells are generally low in number and exhausted.
Michael D. Crowther, Inge Marie Svane, Özcan Met   +2 more
doaj   +1 more source